References
Nandular KR, Dwamena BA, Choudhri AF, Nandalur SR, Reddy P, Carlos RC. Diagnostic performance of positron emission tomography in the detection of coronary artery disease: A meta-analysis. Acad Radiol. 2008;15:444-51.
McArdle BA, Dowsley TF, deKemp RA, Wells GA, Beanlands RS. Does Rubidium-82 have superior accuracy to SPECT perfusion imaging for the diagnosis of obstructive coronary disease? A systematic review and meta-analysis. J Am Coll Cardiol. 2012;60:1828-37.
Parker MW, Iskandar A, Limone B, Perugini A, Kim H, Jones C, et al. Diagnostic accuracy of cardiac positron emission tomography versus single photon emission computed tomography for coronary artery disease. A bivariate meta-analysis. Circ Cardiovasc Imaging. 2012;5:700-7.
Bateman T, Heller GV, McGhie I, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated rubidium-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m-sestamibi SPECT. J Nucl Cardiol. 2006;12:24-33.
Yoshinaga K, Chow BJW, Williams K, Chen L, de Kemp RA, Garrard L, et al. What is the prognostic value of myocardial perfusion imaging using rubidium-82 positron emission tomography? J Am Coll Cardiol. 2006;48:1029-39.
Dorbala S, Dorbala H, Hachamovitch R, Cunillova Z, Thomas D, Vangala D, et al. Incremental prognostic value of gated Rb-82 positron emission tomography myocardial perfusion imaging over clinical variables and rest LVEF. J Am Coll Cardiol Imaging. 2009;2:846-54.
Marwick TH, Shan K, Patel S, Go RT, Lauer MS. Incremental value of rubidium-82 positron emission tomography for prognostic assessment of known or suspected coronary artery disease. Am J Cardiol. 1997;80:865-70.
Lertsburapa K, Ahlberg AW, Bateman TM, Katten D, Volker L, Cullom SJ, et al. Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease. J Nucl Cardiol. 2008;15:745-53.
Dorbala S, DiCarli MF, Beanlands RS, Merhige ME, Williams BA, Veledar E, et al. Prognostic value of stress myocardial perfusion positron emission tomography. J Am Coll Cardiol. 2013;61:176-84.
Ziadi MC, deKemp RA, Williams KA, Guo A, Chow BJ, Renaud JM, et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol. 2011;58:740-8.
Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124:2215-24.
Kajander S, Joutsiniemi E, Saraste M, Pietila M, Ukkonen H, Saraste A, et al. Cardiac positron emission tomography/computed tomography imaging accurately detects anatomically and functionally significant coronary artery disease. Circulation. 2010;122:603-13.
Cerqueira MD, Allman KC, Ficaro EP, Hansen CL, Nichols KJ, Thompson RC. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol. 2010;17:709-18.
Senthamizhchelvan S, Bravo PE, Esaias C, Lodge MA, Merrill J, Hobbs RF, et al. Human biodistribution and radiation dosimetry of 82Rb. J Nucl Med. 2010;51:1592-9.
Senthamizhchelvan S, Bravo PE, Lodge MA, Merrill J, Bengel FM, Sgouros G, et al. Radiation dosimetry of 82Rb in humans under pharmacologic stress. J Nucl Med. 2011;52:485-91.
Einstein AJ. Effects of radiation exposure from cardiac imaging: How good are the data? J Am Coll Cardiol. 2012;59:553-65.
Hunter CRRN, Hill J, Ziadi MC, Beanlands RSB, deKemp RA. Biodistribution and radiation dosimetry of 82Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging. Eur J Nucl Med Mol Imaging. 2015. doi:10.1007/s00259-015-3028-3.
Merhige ME, Breen WJ, Shelton V, Houston T, D’Arcy BJ, Perna AF. Impact of myocardial perfusion imaging with PET and (82)Rb on downstream invasive procedure utilization, costs, and outcomes in coronary disease management. J Nucl Med. 2007;48:1069-76.
Bonow RO, Maurer G, Lee KL, Holly TA, Binkley RF, Desvigne-Nickens P, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med. 2011;364:1617-25.
Mielniczuk LM, Beanlands RS. Does imaging-guided selection of patients with ischemic heart failure for high risk revascularization improve identification of those with the highest clinical benefit? Imaging-guided selection of patients with ischemic heart failure for high-risk revascularization improves identification of those with the highest clinical benefit. Circ Cardiovasc Imaging. 2012;5:262-70.
Beanlands RSB, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease. A randomized controlled trial (PARR-2). J Am Coll Cardiol. 2007;50:2002-12.
Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: Inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6:363-72.
O’Meara E, Mielniczuk LM, Wells GA, deKemp RA, Klein R, Coyle D, et al. Alternative imaging modalities in ischemic heart failure (AIMI-HF) IMAGE HF Project I-A: Study protocol for a randomized controlled trial. Trials. 2013;14:218.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Beanlands, R., Heller, G.V. Proceedings of the ASNC Cardiac PET Summit, 12 May 2014, Baltimore, MD. J. Nucl. Cardiol. 22, 557–562 (2015). https://doi.org/10.1007/s12350-015-0129-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12350-015-0129-0